Disease landscape

Non-Small Cell Lung Cancer (NSCLC) clinical trials

Get alerts when Non-Small Cell Lung Cancer (NSCLC) trials change

2,329 active trials 1,240 recruiting 330 Phase 3 879 sponsors 357 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 46 of 357 changes on 20 trials

2026-09-03
Reclassified as terminated (was completed)
Trial terminated: Study closed by Amgen due to lack of enrollment
NCT06333678 A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… · Memorial Sloan Kettering Cancer Center · Phase 2
2026-08-28
Withdrawn before enrolling
Trial withdrawn: Other - Protocol moved to Withdrawn
Enrollment reduced: 24 → 0 participants
NCT06982222 Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… · National Cancer Institute (NCI) · Phase 1
2026-08-29
Trial status changed: Not Yet Recruiting → Suspended
Recruitment suspended: Administrative
NCT07639242 Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… · UNC Lineberger Comprehensive Cancer Center · Phase 2
2026-08-15
Recruitment suspended
Recruitment suspended: Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.
NCT06694454 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… · National Cancer Institute (NCI) · Phase 1/2
2026-09-04
Primary completion pushed: 2026-10-31 → 2027-06-30
Trial sites reduced: 164 → 161 locations
Completion pushed: 2026-10-31 → 2027-06-30
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… · Hoffmann-La Roche · Phase 2/3
2026-09-05
Primary completion pushed: 2025-12-09 → 2027-06
Recruitment opened
Completion pushed: 2026-04-03 → 2027-12
NCT06641609 A Phase I Study of CFT8919 in Patients With Advanced NSCLC · Betta Pharmaceuticals Co., Ltd. · Phase 1
2026-09-05
Primary completion pushed: 2027-02 → 2029-06
Primary endpoint(s) modified
Enrollment increased: 495 → 575 participants
Interventions modified
Completion pushed: 2027-04 → 2029-06
Trial arms changed: 9 → 11
NCT06400472 A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · Eli Lilly and Company · Phase 1
2026-09-03
Primary completion pushed: 2026-03 → 2027-03
Completion pushed: 2026-03 → 2027-03
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy… · AbbVie · Phase 1
2026-09-03
Primary completion pushed: 2026-12-31 → 2027-12-31
Completion pushed: 2027-01-29 → 2028-01-29
NCT06049212 Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in… · Merck Sharp & Dohme LLC · Phase 1
2026-09-03
Primary completion pushed: 2026-07-01 → 2027-07-01
Completion pushed: 2026-07-01 → 2028-07-01
NCT06097962 Safety and Efficacy of NK510 to Treat NSCLC · Base Therapeutics (Shanghai) Co., Ltd. · Early Phase 1
2026-09-02
Primary completion pushed: 2027-01-01 → 2028-01-01
Completion pushed: 2027-01-01 → 2028-01-01
NCT03401385 First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) · Daiichi Sankyo Co., Ltd. · Phase 1
2026-09-03
Primary completion pushed: 2026-07-31 → 2026-11-12
Completion pushed: 2026-07-31 → 2026-11-12
NCT07413757 CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · AstraZeneca
2026-08-29
Primary completion pushed: 2026-08-13 → 2027-01-31
Enrollment closed, study ongoing
Completion pushed: 2027-02-13 → 2027-05-31
NCT06475937 A Study of DM001 in Patients With Advanced Solid Tumors · Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Phase 1
2026-08-26
Primary completion pushed: 2025-06-30 → 2025-12-15
Completion pushed: 2027-12-30 → 2030-03-30
NCT05948813 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases · TYK Medicines, Inc · Phase 2
2026-08-29
Primary completion pushed: 2035-01-31 → 2039-04-01
Completion pushed: 2035-01-31 → 2039-04-01
NCT06096844 Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With… · National Cancer Institute (NCI) · Phase 3
2026-08-14
Primary completion pushed: 2026-01 → 2026-12
NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With… · Allist Pharmaceuticals, Inc. · Phase 3
2026-08-14
Primary completion pushed: 2026-09-30 → 2029-09-30
Completion pushed: 2027-02-28 → 2030-08
NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… · Allist Pharmaceuticals, Inc. · Phase 3
2026-09-04
Primary completion pushed: 2026-07-10 → 2027-08-10
NCT07089199 Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell… · Qilu Hospital of Shandong University · Phase 2
2026-09-04
Primary completion pushed: 2026-09-30 → 2029-09-30
Completion pushed: 2026-09-30 → 2029-09-30
NCT04892953 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage… · M.D. Anderson Cancer Center · Phase 2
2026-08-14
Primary completion pushed: 2026-03 → 2027-03
Completion pushed: 2026-03 → 2027-03
NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… · Allist Pharmaceuticals, Inc. · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-27 NCT07789444 Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets Xiaorong Dong new Phase 2
2026-08-25 NCT07783971 Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics… 958th Army Hospital of the Chinese People's Liberation Army new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-20 NCT07776353 Understanding New Cachexia Subtypes Through Observational Epidemiological Research Kaiser Permanente new
2026-08-18 NCT07771764 A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as… First Affiliated Hospital of Fujian Medical University new Phase 2
2026-08-18 NCT07770100 Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy… Mark Bernard new Phase 2
2026-08-10 NCT07755397 First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety… Jubilant Therapeutics India Limited new Phase 1
2026-08-03 NCT07742800 Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer… HAN GUANG new
2026-08-03 NCT07743021 Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data Center for Molecular Fingerprinting Research Nonprofit LLC new
2026-07-20 NCT07714304 JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC Huan Zhou new

Active trials by phase

Early Phase 1
24
Phase 1
335
Phase 1/2
275
Phase 2
733
Phase 2/3
42
Phase 3
288
Phase 4
28
Not charted: 604 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 2,329

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Novartis Pharmaceuticals Recruiting 2026-09-04
NCT07279935 Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… AstraZeneca Recruiting 2026-08-27
NCT06908070 Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab Idris Bahce Recruiting 2026-08-20
NCT07704658 Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Rigel Pharmaceuticals Recruiting 2026-08-10
NCT07754812 Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… Shanghai Pulmonary Hospital, Shanghai, China Recruiting 2026-08-10
NCT07744698 Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… Anhui Provincial Cancer Hospital Recruiting 2026-08-04
NCT07405086 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… OHSU Knight Cancer Institute Recruiting 2026-06-12
NCT06646471 PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With… GFPC Investigation Recruiting 2026-04-29
NCT06330038 Anesthesia and Non-small Cell Lung Cancer Recurrence Samsung Medical Center Recruiting 2026-04-20
NCT07320105 Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy… Fujian Cancer Hospital Recruiting 2026-01-06
NCT07092202 Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC… Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting 2025-07-29
NCT05748093 Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With… Maastricht University Medical Center Recruiting 2024-08-09
NCT05525338 Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib… University Medical Center Groningen Recruiting 2024-05-13
NCT05172739 Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in… University of Crete Recruiting 2021-12-29
NCT07768358 Tucatinib Continuation Study Pfizer Not Yet Recruiting 2026-08-28
NCT05144997 Lorlatinib Continuation Study Pfizer Active, Not Recruiting 2026-08-26
NCT07674368 Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed Hunan Cancer Hospital Not Yet Recruiting 2026-07-01
NCT07671560 Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant… Qiming Wang Not Yet Recruiting 2026-06-26
NCT07633613 Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor… Centre Antoine Lacassagne Not Yet Recruiting 2026-06-08
NCT06282874 Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Guangdong Association of Clinical Trials Active, Not Recruiting 2026-04-09
NCT05160922 Crizotinib Continuation Clinical Study Pfizer Active, Not Recruiting 2026-03-30
NCT07469488 A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM)… Shanghai Pulmonary Hospital, Shanghai, China Not Yet Recruiting 2026-03-13
NCT05689671 Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… Nikolaj Frost MD Active, Not Recruiting 2026-03-10
NCT04413201 AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib… Michael Hopp Active, Not Recruiting 2025-03-25
NCT06893354 Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance… The First Affiliated Hospital of Guangzhou Medical University Not Yet Recruiting 2025-03-25
See all 2,329 active Non-Small Cell Lung Cancer (NSCLC) trials with filters →

Top sponsors by active trials in this area

AstraZeneca (79) · National Cancer Institute (NCI) (43) · Shanghai Pulmonary Hospital, Shanghai, China (40) · Sun Yat-sen University (37) · Fudan University (35) · M.D. Anderson Cancer Center (32) · Shanghai Chest Hospital (30) · Tianjin Medical University Cancer Institute and Hospital (28) · Hunan Province Tumor Hospital (27) · Merck Sharp & Dohme LLC (26)

Get alerts when Non-Small Cell Lung Cancer (NSCLC) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free